Personalized cancer therapies are quickly becoming the preferred method of treatment for many cancer patients. Identification of the cause of carcinogenesis is the first step in determining which personalized therapies can be utilized. While understanding and identifying each person’s cancer-specific mutations can be difficult, finding therapies to target them can be even more challenging. My project aims to combat this by utilizing the overexpression of enzymes in cancerous cells as a target for novel chemotherapies. Identifying and optimizing new therapeutic molecules will help us diversify our arsenal of anti-cancer drugs.
Advisor: Paul Hergenrother
Degree: PhD 2022
Current Position: Senior Scientist at Arrakis Therapeutics